A daily pellet can be effective as aid to reduce blood sugar and help weight loss in people with type 2 diabetes, according to the results of a clinical trial, popular injection drugs mounjaro and ozmpic. Declared by Ellie Lily Thursday morning.
The drug, Orforglipron, is a GLP-1, a class of drugs that have become a blockbuster due to the effect of their weight loss. But GLP-1s are expensive, they should be kept refrigerated and injected. A tablet that produces similar results has the ability to use more widely, although it is also expected to be expensive.
“In the coming decades, more than 700 million people worldwide will have type 2 diabetes, and will have more than one billion,” Lily’s Chief Scientist Officer Dr. Daniel Scovronsky said. “Injections may not be a solution for billions of people around the world.”
Lily said it would demand approval to orfliprypron for obesity from Food and Drug Administration later this year and in 2026 in 2026. Industry analysts hope that the drug will win approval for some time next year and eventually become a major blockbuster. Eli Lily does not expect to declare a price for the drug until it wins the approval.
The company announced a summary of its results in a news release on Thursday, as pharmaceutical companies need to do the results of the study that can affect their stock price. The company said that it would present detailed results in the meeting of diabetes researchers in June and publish them in a colleague reviewed by a colleague.
But Lily did not release the underlying data from her test and the results mentioned by it were not examined by external experts.
The clinical test consisted of 559 people with type 2 diabetes who took a new tablet or placebo for 40 weeks. In patients taking orfliprons, blood sugar levels fell from 1.3 to 1.6 percent, as measured by A1C, about the same amount in the time period that was experienced by patients taking ozmpic and silent in unrelated tests. For 65 percent of the new pill -taking people, blood sugar levels fell into the normal range.
Patients also lost weight on the new pill – up to 16 pounds without reaching a plateau at the end of the study. His weight was similar to losing loss that was obtained with ozmpic in 40 weeks, but unrelated tests were slightly lower than silent.
Side effects were similar to injected obesity drugs – diarrhea, indigestion, constipation, nausea and vomiting.
It is possible that when the drug is used in a large number of patients, the benefits may be small and the side effects may be worse.
Elly Lily is in front of a packet of companies running to develop GLP -1 bullets, and there are major concerns that such pills can cause harsh side effects that discourage patients to take them. Earlier this week, Fizer Said that it was decided After a test participant experienced a “potential drug -induced liver injury” to prevent a GLP -1 pill from developing.
Ellie Lily’s stock increased on encouraging data. When the market was opened on Thursday, it increased by 14 percent when adding $ 100 billion to the company’s market price.
This was the first of the seven major clinical trials of Orforglipron to report the results. Some other diabetes are testing the drug for weight loss in people without diabetes. Results in obesity patients are expected to be at the end of this year.
If the medicine is approved for obesity and diabetes, then Dr. Skopavronesky said, the company is confident that it will have sufficient amounts of bullets to meet the demand. He said that he had learned the results of diabetes studies on Tuesday morning, but the company was preparing supply without leaving them.
Twelve percent American adults say they have taken GLP-1. About 40 percent Americans are thick, and more than 10 percent According to the disease control and prevention centers, most of which have type 2.
In a way, the great existence of Orforglipron is the victory of modern chemistry. Injectable GLP-1 drugs are peptides-small pieces of-paint. (GLP means glucagon -like peptide.) Peptides are digested from the stomach. Therefore, to create an oral GLP-1, chemists had to find a way to make a nonpeptide that acts exactly like peptide. Researchers at a Japanese company, Chugai Pharmaceutical Company found a way, licensed Lily to their drug in 2018.
The solution was to find a small molecule-a thousandth of a peptide-shaped thousandth-which is submerged in a small pocket in protein that aims for GLP-1S. When it sinks into the pocket, the protein shape changes as it occurs when a GLP-1 binds the entire protein.
Finding that small molecule, Dr. Scotvronesky said, “the holy grave”.
Result-A tablet that can be taken at any time of the day, with or without food is almost unheard of the world of drugs. Insulin, perhaps the most common peptide drug, is from more than 50 years. It is still an injection despite intensive efforts by scientists to make only an insulin pill. So human development is hormone. Therefore, there are medicines used to treat various types of diseases including arthritis and cancer.
Novo Nordisk has a GLP-1 tablet, rybelsus, but contains GLP-1 peptide, so it should be taken in large doses and is not as effective as injectables because most of it is digested.
But for diabetic patients and people struggling with obesity, a pill that can change an injection can be transformative for several reasons.
One is that it can make treatment attractive for those who cannot consider to be injecting themselves.
Professor of the drug at Harvard and Chief Educational Officer at Josalin Diabetes Center in Harvard. C. Ronald Kahan said that he had many patients who were reluctant to inject themselves with Ozapics or Munjaro.
A bullet, he said, “will definitely be preferred by most people.”
Director of Wharton Medical Clinic at Burlington, Ontario, Dr. Sean Wharton has a widespread hope. Dr. Wharton, who enrolled patients in the study of Lily’s Lily’s Lily’s Lily, said that a pill could potentially bring GLP -1 treatment for population worldwide.
“It can easily be made in a factory and can be sent everywhere,” he said. It should spend much less than peptides and does not require packaging in special injection pens. There is no need to keep it refrigerated.
For now, drugs are available only for a small part of those who have insurance coverage or can pay them out of the pocket. He had access to rich countries only.
This is the beginning of changing: Ellie Lily recently Launched Its injected drug silence in India. As soon as the injection drug of Novo Nordisk is expected to go normal in some countries, although not in the United States.
With Orflipron, “We have the opportunity for medicine to be given to millions and millions of people,” Dr. Wharton said.
But it depends on Ellie Lily and how it distributes value and its medicine.
“This is why I emphasize the word ‘opportunity’,” Dr. Wharton said.
